| Knockout Cell Lines |
| 2fTGH IFNg KO Series |
Panel of IFNg signalling mutant lines derived from 2fTGH fiborsarcoma cell line, each contains a different mutation in the IFN signalling pathway |
| p300-1 |
Somatic p300 knockout colon carcinoma cell line (derived from HCT116) |
| |
| Transgenic Cell Lines |
| CH7C17 |
T lymphoid cell line expressing stable, functional CD3 and TCR specific to influenza haemagglutinin peptide (HA307-319, in context of HLA-DR1 MHCII molecule) |
| MTSV1-7 ce1 |
Human mammary luminal epithelial cell line MTSV1-7 overexpressing ERBB2 |
| |
| Tumour Lines / Panels |
| CMT 167 |
Highly metastatic murine alveogenic lung carcinoma tumour line (subclone of CMT 64) |
| CMT 64 |
Murine alveogenic lung carcinoma tumour line exhibiting stable growth characteristics and morphology |
| JIM1 |
Myeloma cell line with typical plasma cell phenotype (CD38, PCA-1 8A, CD24 positive) deficient in DNA repair (derived from pleural fluid of advanced multiple myeloma patient) |
| JIM3 |
Myeloma cell line with typical plasma cell phenotype (CD38, PCA-1 8A, CD24 positive) deficient in DNA repair (derived from pleural fluid of advanced multiple myeloma patient) |
| PE Ovarian Adenocarcinoma Series |
Ovarian adenocarcinoma tumour panel (derived from varying sites and treatment stages) |
| |
| Embryonic Stem Cells |
| B6.1.1 & B6.2.1 |
Mouse embryonic stem cell clones derived from C57BL/6 mouse strain (C57BL/6 ES cells) |
| |
| Viral Packaging Cell Lines |
| FLYA13 |
HT1080-based recombinant retrovirus packaging cell line (Moloney MLV cores, amphotropic MLV envelopes) |
| FLYRD18 |
HT1080-based recombinant retrovirus packaging cell line (Moloney MLV cores, cat endogenous virus RD114 envelopes) |
| WE & pBabe gene transfer system |
NIH 3T3-based recombinant retrovirus packaging cell line (WE) and shuttle vector (pBabe) for production of Moloney MLV vectors) |
| |
| Tumourigenesis Models |
| CMT 167 |
Highly metastatic murine alveogenic lung carcinoma tumour line (subclone of CMT 64) |
| CMT 64 |
Murine alveogenic lung carcinoma tumour line exhibiting stable growth characteristics and morphology |
| |
| Drug Efficacy / Toxicity |
| 2fTGH IFNg KO Series |
Panel of IFNg signalling mutant lines derived from 2fTGH fiborsarcoma cell line, each contains a different mutation in the IFN signalling pathway |
| CH7C17 |
T lymphoid cell line expressing stable, functional CD3 and TCR specific to influenza haemagglutinin peptide (HA307-319, in context of HLA-DR1 MHCII molecule) |
| PE Ovarian Adenocarcinoma Series |
Ovarian adenocarcinoma tumour panel (derived from varying sites and treatment stages) |
| |
| Morphogenesis / Adhesion Properties |
| 1-7HB2 |
Human mammary luminal epithelial cell line demonstrating branching morphology in co-culture with fibroblasts (subclone of MTSV1-7) |
| MTSV1-7 ce1 |
Human mammary luminal epithelial cell line MTSV1-7 overexpressing ERBB2 |
| p300-1 |
Somatic p300 knockout colon carcinoma cell line (derived from HCT116) |
| |
| T Cell Receptor Function |
| CH7C17 |
T lymphoid cell line expressing stable, functional CD3 and TCR specific to influenza haemagglutinin peptide (HA307-319, in context of HLA-DR1 MHCII molecule) |
| |
| |
For further information about cell lines from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Click here to view disclaimer information. |
